Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Pedigo

Physician Assistant Denton, TX Physician Assistant

NPI 1144798570 CMS profile 11097743

2900 N I 35 Ste 301, Denton, TX 76201

Open in the dashboard

General payments

$12,326

731 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Pedigo of Denton, TX is reported in the CMS Open Payments database as having received $12,326 across 731 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,336 195
2024 General $2,066 115
2023 General $3,120 184
2022 General $2,223 132
2021 General $1,580 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Pedigo
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Mark Pedigo were reported at $3,336. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Mark Pedigo Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,580 $132 $37–$438 $132
2022 $2,223 $155 $48–$522 $149
2023 $3,120 $167 $52–$557 $160
2024 $2,066 $178 $55–$600 $164
2025 $3,336 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $1,458 91 payments
  2. AstraZeneca Pharmaceuticals LP $1,291 78 payments
  3. AbbVie, Inc. $1,272 82 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $566 36 payments
  5. Lilly USA, LLC $565 36 payments
  6. GlaxoSmithKline, LLC. $550 28 payments
  7. Amgen Inc. $530 39 payments
  8. Otsuka America Pharmaceutical, Inc. $490 24 payments
  9. Pfizer Inc. $449 25 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $422 26 payments
  11. Other $4,734 266 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,264 730 payments
  2. Education $62 1 payment
Products named General payments · program years 2021–2025
  1. FARXIGA $917 55 payments
  2. Ozempic $897 56 payments
  3. RYBELSUS $763 49 payments
  4. Kerendia $566 36 payments
  5. UBRELVY $496 28 payments
  6. REXULTI $490 24 payments
  7. Repatha $365 26 payments
  8. TRELEGY ELLIPTA $357 18 payments
  9. VRAYLAR $350 20 payments
  10. MOUNJARO $333 20 payments
  11. Other $9,935 592 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 111 drugs

Part D claims

4,175

Median for Physician Assistant: 241

Drug cost

$444,935

Median for Physician Assistant: $4,110

Branded share of claims

20.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 60 $96,995
Jardiance Empagliflozin Brand 70 $73,116
Mounjaro Tirzepatide Brand 48 $67,816
Farxiga Dapagliflozin Propanediol Brand 22 $31,181
Eliquis Apixaban Brand 26 $23,060
Repatha Sureclick Evolocumab Brand 16 $22,479
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 16 $18,939
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $17,390
Elmiron Pentosan Polysulfate Sodium Brand 12 $9,605
Myrbetriq Mirabegron Brand 13 $9,422

The 10 drugs with the highest cost, of 111 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$52,308

Of which drugs: $6,928

Medicare patients

294

Average age 74

Services billed

1,589

127 women, 167 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Ischemic heart disease 33%
Chronic kidney disease 27%
Diabetes 25%
Depression 22%
COPD 19%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,779
Vaccine for influenza for injection into muscle 90662 Office 34 34 $2,782

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 40 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
$159 — —
FARXIGA
$119 22 —
VOQUEZNA
$92 — —
RYBELSUS
$92 — —
Ozempic
$92 60 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 40 with Patron

Records

731 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record